Oral pill improves care of patients with bone marrow cancer: Study
<p>Results of MOMENTUM myelofibrosis clinical trial presented at ASCO 2022 Contact: Will Sansom, 210-567-2579, sansom@uthscsa.edu CHICAGO AND SAN ANTONIO (June 7, 2022) — Momelotinib, an oral pill taken once a day, significantly improved outcomes of patients treated for myelofibrosis (MF), a rare but fatal bone marrow cancer, researchers reported June 7. Ruben Mesa, MD, FACP, […]</p>